Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis

Tuberculosis Clinical Trial

— REFLATE TB2  

Official title:

Phase III Open-label Randomized Multicenter Trial to Assess the Non-inferiority of Raltegravir Compared With EFavirenz, Both in Combination With LAmivudine and TEnofovir, in ART-naïve HIV-1-infected Patients Receiving Rifampin for Active TuBerculosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02273765
• Other study ID #: ANRS 12300 REFLATE TB2
• Status: Completed
• Phase: Phase 3
• Start date: September 11, 2015
• Est. completion date: November 28, 2018

Study information

• Verified date: December 2018
• Source: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Phase III trial evaluating raltegravir as an alternative to efavirenz for antiretroviral treatment of HIV-infected patients with tuberculosis.

Description:

Phase III multicenter, international, open-label, randomized trial evaluating non-inferiority of raltegravir at dose of 400mg BID compared to efavirenz 600mg QD, both in association with tenofovir disoproxil fumarate and lamivudine in ART-naïve HIV-1 infected patients with active TB disease receiving a rifampin-based TB treatment initiated <8 weeks before inclusion. Patients will be randomized between 2 arms: the raltegravir (RAL) 400 mg bid arm or the efavirenz (EFV) 600 mg qd arm, each in combination with tenofovir disoproxil fumarate (TDF) and lamivudine (3TC) and will be followed for 48 weeks after entry in the trial (ART initiation).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 460
• Est. completion date: November 28, 2018
• Est. primary completion date: November 28, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Signed informed consent form

• Aged 18 years or more

• Confirmed HIV-1 infection as documented at any time prior to trial entry per national HIV testing procedures

• ART naïve

• For women of childbearing potential i.e. women of childbearing age who are not menopausal, or permanently sterilized (e.g. tubal occlusion, hysterectomy, bilateral salpingectomy) or not refraining from sexual activity: negative urinary test for pregnancy and acceptance to use contraceptive methods

• Confirmed or probable active TB disease of any location, except neurological (meningitis or encephalitis), according to the following criteria based on WHO updated definitions:

• Bacteriologically confirmed pulmonary TB (PTB) or extrapulmonary TB (EPTB), e.g. TB with a biological specimen positive by smear microscopy, culture or nucleic acid amplification test (such as Xpert MTB/RIF).

• Clinically diagnosed PTB or EPTB with typical histological evidence of TB (caseous or granulomatous) on biopsy specimen or positive urinary LAM test OR a significant improvement on TB treatment

• Ongoing standard rifampin-containing TB treatment for =8 weeks at inclusion

• For French patients, affiliation to a Social Security program

Exclusion Criteria:

• HIV-2 co-infection

• Impaired hepatic function (icterus or ALT (SGPT) > 5ULN)

• Hemoglobin < 6.5 g/dl

• Creatinine clearance <60ml/min (assessed by the Cockroft and Gault formula)

• Mycobacterium tuberculosis strain resistant to rifampin (current or past history).

• Neurological TB (meningitis or encephalitis)

• Severe associated diseases requiring specific treatment (including all specific AIDS defining illnesses other than TB, and any severe sepsis)

• Any condition which might, in the investigator's opinion, compromise the safety of treatment and/or patient's adherence to trial procedures including very severe TB-related clinical condition

• Concomitant treatments including phenytoin or phenobarbital (compounds interacting with UGT1A1)

• For HCV co-infected patients, need to start specific treatment for hepatitis during the trial duration

• For women of childbearing potential:

• Pregnancy or breastfeeding

• Refusal to use a contraceptive method

• Any history of ARV intake for prevention of mother to child transmission of HIV (pMTCT)

• Subjects participating in another clinical trial evaluating therapies and including an exclusion period that is still in force during the screening phase

• Person under guardianship, or deprived of freedom by a judicial or administrative decision

Related Conditions & MeSH terms

• HIV-1 Infection
• Tuberculosis

Intervention

Drug:
• Tenofovir + lamivudine + raltegravir
In this arm, patients will receive the following medications : Tenofovir disoproxil fumarate (TDF) 300 mg / Lamivudine (3TC) 300 mg FDC once a day (1 tablet qd) Raltegravir (RAL) 400 mg (Isentress®): twice daily (1 tablet bid), with food In countries where TDF/3TC FDC is not available, the following separate drugs will be used: Tenofovir disoproxil fumarate (TDF) 300 mg (Viread® 245 mg): once a day (1 tablet qd) Lamivudine (3TC) : 300 mg once a day (300 mg, 1 tablet qd or 150 mg 2 tablets qd) Raltegravir (RAL) 400 mg (Insentress®): twice daily (1 tablet bid), with food
• Tenofovir + lamivudine + efavirenz
In this arm, patients will receive the following medications, in accordance with treatment guidelines in all countries: Tenofovir disoproxil fumarate (TDF) 300 mg / lamivudine (3TC) 300 mg FDC once a day (1 tablet qd) Efavirenz (EFV) 600 mg: once a day, at night (1 tablet qd) OR: • Tenofovir disoproxil fumarate (TDF) 245 300 mg / lamivudine (3TC) 300 mg / efavirenz (EFV) 600 mg: once a day (1 tablet qd), at night, if possible without food In countries where TDF/3TC FDC is not available, the following separate drugs will be used: Tenofovir disoproxil fumarate (TDF) 300 mg (Viread® 245 mg): once a day (1 tablet qd) Lamivudine (3TC): 300 mg once a day (300 mg, 1 tablet qd or 150 mg 2 tablets qd) Efavirenz (EFV) 600 mg: once a day, at night (1 tablet qd), if possible without food. The dose will not be adapted to the patient's body weight.

Locations

Country	Name	City	State
Brazil	Laboratory of clinical research on STD/AIDS - IPEC/FIOCRUZ	Rio de Janeiro
Côte D'Ivoire	PACCI / CePReF Centre de Prise en charge de Recherche et de Formation	Abidjan
France	Hôpital Saint Louis	Paris
Mozambique	Instituto Nacional de Saude / Hospital Geral de Machava	Maputo
Vietnam	Pham Ngoc Thach Hospital	Ho Chi Minh City

Sponsors (3)

Lead Sponsor	Collaborator
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)	Merck Sharp & Dohme Corp., Ministry of Health, Brazil

Countries where clinical trial is conducted

Brazil,  Côte D'Ivoire,  France,  Mozambique,  Vietnam, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of patients in virologic success	Virologic success, defined as plasma HIV-1 RNA <50 copies/mL, at week 48 with a window period of 42 to 54 weeks (snapshot algorithm). Discontinuation of the strategy (ie. permanent discontinuation of EFV, RAL), missing values, loss to follow-up and death will be considered as failure.	Week 48
Secondary	Time to death		Week 48
Secondary	Frequency, type and time to new or recurrent AIDS-defining illnesses		Week 48
Secondary	Frequency, type and time to severe HIV-associated non-AIDS defining illnesses		Week 48
Secondary	Frequency, type and time to grade 3 or 4 adverse events		Week 48
Secondary	Frequency, type and time to drug-induced clinical or biological adverse reactions of grade 3 or 4 or leading to treatment interruption		Week 48
Secondary	Change in plasma HIV-1 RNA from baseline to week 48		Week 48
Secondary	Proportion of patients in virologic success at each time point (HIV-1 RNA<50 copies/mL)		Week 48
Secondary	Time to virologic failure during follow-up		Week 48
Secondary	Frequency and time to new antiretroviral genotypic resistance in plasma RNA in patients with virologic failure		Week 48
Secondary	Change in CD4 cell counts from baseline to week 48		Week 48
Secondary	Frequency, type and time to Immune Reconstitution Inflammatory Syndrome		Week 48
Secondary	Frequency of tuberculosis treatment outcomes		Week 48